Page last updated: 2024-10-28

guanfacine and Benign Psychomotor Epilepsy, Childhood

guanfacine has been researched along with Benign Psychomotor Epilepsy, Childhood in 1 studies

Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Swartz, BE1
Kovalik, E1
Thomas, K1
Torgersen, D1
Mandelkern, MA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885]16 participants (Actual)Interventional2008-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Inferior Parietal Lobule

"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Interventionpercent change in saline signal (Mean)
Guanfacine-0.17
Placebo-0.094

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Middle Frontal Gyrus

Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Interventionpercent change in saline signal (Mean)
Guanfacine-0.1
Placebo0.052

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Superior Frontal Gyrus

Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Interventionpercent change in saline signal (Mean)
Guanfacine-0.134
Placebo-0.086

Trials

1 trial available for guanfacine and Benign Psychomotor Epilepsy, Childhood

ArticleYear
The effects of an alpha-2 adrenergic agonist, guanfacine, on rCBF in human cortex in normal controls and subjects with focal epilepsy.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2000, Volume: 23, Issue:3

    Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Blood Pressure; Cerebral Cor

2000